Ciprofloxacin	O
mediated	O
cell	B-Cell
growth	O
inhibition	O
,	O
S	O
/	O
G2	O
-	O
M	O
cell	B-Cell
cycle	O
arrest	O
,	O
and	O
apoptosis	O
in	O
a	O
human	O
transitional	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
of	O
the	O
bladder	B-Cell
cell	I-Cell
line	I-Cell
.	O

The	O
second	O
most	O
prevalent	O
urological	B-Cancer
malignancy	I-Cancer
in	O
middle	O
aged	O
and	O
elderly	O
men	O
is	O
bladder	B-Cancer
cancer	I-Cancer
,	O
with	O
90	O
%	O
of	O
the	O
cases	O
being	O
transitional	B-Cancer
cell	I-Cancer
carcinomas	I-Cancer
.	O

The	O
success	O
of	O
current	O
systemic	O
and	O
intravesical	O
therapeutic	O
agents	O
,	O
such	O
as	O
cisplatin	O
,	O
thiotepa	O
,	O
Adriamycin	O
,	O
mitomycin	O
C	O
,	O
and	O
bacillus	O
Calmette	O
-	O
Guerin	O
,	O
is	O
limited	O
with	O
recurrence	O
rates	O
reduced	O
to	O
17	O
-	O
44	O
%	O
.	O

In	O
addition	O
,	O
most	O
of	O
these	O
agents	O
require	O
instrumentation	O
of	O
the	O
urinary	B-Organism_subdivision
tract	I-Organism_subdivision
and	O
are	O
delivered	O
at	O
a	O
significant	O
cost	O
and	O
potential	O
morbidity	O
to	O
the	O
patient	O
.	O

Fluroquinolone	O
antibiotics	O
such	O
as	O
ciprofloxacin	O
,	O
which	O
can	O
be	O
administered	O
p	O
.	O
o	O
.	O
,	O
may	O
have	O
a	O
profound	O
effect	O
in	O
bladder	B-Cancer
cancer	I-Cancer
management	O
.	O

This	O
is	O
primarily	O
based	O
on	O
limited	O
in	O
vitro	O
studies	O
on	O
tumor	B-Cell
cells	I-Cell
derived	O
from	O
transitional	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
of	O
the	O
bladder	B-Organ
that	O
revealed	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
cell	B-Cell
growth	O
by	O
ciprofloxacin	O
at	O
concentrations	O
that	O
are	O
easily	O
attainable	O
in	O
the	O
urine	B-Organism_substance
of	O
patients	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
ciprofloxacin	O
elicits	O
its	O
biological	O
effects	O
on	O
bladder	B-Cell
cancer	I-Cell
cells	I-Cell
is	O
not	O
well	O
documented	O
.	O

Our	O
experimental	O
data	O
confirm	O
previous	O
studies	O
showing	O
the	O
in	O
vitro	O
cell	B-Cell
growth	O
inhibition	O
of	O
the	O
transitional	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
of	O
the	O
bladder	B-Cell
cell	I-Cell
line	I-Cell
HTB9	I-Cell
and	O
further	O
showed	O
the	O
induction	O
of	O
cell	B-Cell
cycle	O
arrest	O
at	O
the	O
S	O
/	O
G2	O
-	O
M	O
checkpoints	O
.	O

In	O
addition	O
,	O
we	O
found	O
down	O
-	O
regulation	O
of	O
cyclin	O
B	O
,	O
cyclin	O
E	O
,	O
and	O
dephosphorylation	O
of	O
cdk2	O
in	O
ciprofloxacin	O
-	O
treated	O
bladder	B-Cell
tumor	I-Cell
cells	I-Cell
.	O

There	O
was	O
also	O
an	O
up	O
-	O
regulation	O
of	O
Bax	O
,	O
which	O
altered	O
the	O
Bax	O
:	O
Bcl	O
-	O
2	O
ratio	O
,	O
which	O
may	O
be	O
responsible	O
for	O
mitochondrial	B-Cellular_component
depolarization	O
reported	O
to	O
be	O
involved	O
prior	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21WAF1	O
level	O
was	O
found	O
to	O
be	O
decreased	O
within	O
12	O
h	O
of	O
ciprofloxacin	O
treatment	O
and	O
disappeared	O
completely	O
when	O
HTB9	B-Cell
cells	I-Cell
were	O
treated	O
with	O
200	O
microg	O
/	O
ml	O
ciprofloxacin	O
for	O
24	O
h	O
.	O

The	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
closely	O
correlated	O
with	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
and	O
CPP32	O
activation	O
.	O

Recent	O
studies	O
revealed	O
that	O
p21WAF1	O
protects	O
cells	B-Cell
from	O
apoptosis	O
by	O
arresting	O
them	O
in	O
G1	O
and	O
further	O
binds	O
to	O
pro	O
-	O
caspase	O
-	O
3	O
,	O
preventing	O
its	O
activation	O
and	O
thus	O
,	O
inhibiting	O
the	O
apoptotic	O
cascade	O
.	O

Hence	O
,	O
the	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
,	O
together	O
with	O
the	O
alterations	O
in	O
Bax	O
and	O
cdk2	O
as	O
observed	O
in	O
our	O
studies	O
,	O
may	O
define	O
a	O
novel	O
mechanism	O
by	O
which	O
ciprofloxacin	O
inhibits	O
tumor	B-Cell
cell	I-Cell
growth	O
and	O
induces	O
apoptotic	O
cell	B-Cell
death	O
.	O

The	O
results	O
of	O
our	O
current	O
studies	O
provide	O
strong	O
experimental	O
evidence	O
for	O
the	O
use	O
of	O
ciprofloxacin	O
as	O
a	O
potential	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
the	O
management	O
of	O
transitional	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
of	O
the	O
bladder	B-Organ
.	O

